NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.

The gene therapy cell culture media market in North America, Europe, and Asia-Pacific is poised for growth due to rising clinical trials, increased biomanufacturing, and demand for GMP-compliant media ...

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

Aviva Bio is advancing AVA-291 (d3-T) as a differentiated testosterone in a broad development program addressing multiple ...

A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers at the University of Southampton have identified a new strategy that could ...

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

That’s only one problem. Your immune system also has an adaptive system of specialized immune cells and antibodies that attack and destroy invading microbes. This system remembers what those intruders ...

The immune system remains seriously out-of-whack—in an inflammatory state of overactivation and impaired functionality—following the international gold standard for treating people with latent ...

Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which ...

Let’s say it’s 2036, and scientists are working on a new class of drugs. Today, for instance, pharmaceutical companies use ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...